Menu
Menu
Question:
I’ve heard there are updates on coverage for NGS and germline cancer, is this true?
Answer:
Yes. After evaluation, the Centers for Medicare & Medicaid Services (CMS) reached the decision that next-generation sequencing (NGS) performed as a diagnostic laboratory test is reasonable and necessary and covered nationally for patients with germline cancer (90.2). The information was presented in transmittal 10346 on September 11, 2020. This is effective for services performed starting on or after January 27, 2020, with the implementation date falling on November 13, 2020. These tests must be performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.
This question was answered in an edition of our Laboratory Compliance Manager. For more hot topics relating to laboratory services, please visit our store or call us at 1.800.252.1578, ext. 2.
CPT® copyright 2023 American Medical Association (AMA). All rights reserved.
Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
CPT is a registered trademark of the American Medical Association.
Subscribe to receive our News, Insights, and Compliance Question of the Week delivered right to your inbox.
Address:Â 5874 Blackshire Path, #13, Inver Grove Heights, MN 55076
Phone:Â (800) 252-1578
Email:Â support@medlearnmedia.com
Hours:Â 9am – 5pm CT
Copyright © 2024 MedLearn Publishing. Powered by MedLearn Media.
Happy World Health Day! Our exclusive webcast, ‘2024 SDoH Update: Navigating Coding and Screening Assessment,’ Â is just $99 for a limited time! Use code WorldHealth24 at checkout.